You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,714,103


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,714,103
Title:Peptides, derivatives and analogs thereof, and methods of using same
Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and/or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.
Inventor(s): Levetan; Claresa S. (Bryn Mawr, PA), Upham; Loraine V. (Mt. Laurel, NJ)
Assignee: CureDM, Inc. (Wynnewood, PA)
Application Number:12/121,123
Patent Claims:1. An isolated human proislet peptide consisting of the amino acid sequence of SEQ ID No: 7.

2. The human proislet peptide of claim 1 further comprising conjugating the amino acid sequence of SEQ TD NO: 7 to a compound selected from albumin, transferrin and polyethylene glycol.

3. The human proislet peptide of claim 2 wherein the compound is polyethylene glycol.

4. The human proislet peptide of claim 2 wherein said compound is covalently linked to the human proislet peptide.

5. The human proislet peptide of claim 2, wherein said compound is non-covalently linked to the human proislet peptide.

6. A pharmaceutical composition comprising a therapeutic amount of the human proislet peptide consisting of the amino acid sequence of SEQ ID No: 7 and an excipient.

7. The pharmaceutical composition of claim 6 further comprising conjugating the amino acid sequence of SEQ ID No: 7 to a compound selected from albumin, transferrin and polyethylene glycol.

8. The pharmaceutical composition of claim 7 wherein said compound is polyethylene glycol.

9. The pharmaceutical composition of claim 6, wherein said compound is covalently linked to the human proislet peptide.

10. The pharmaceutical composition of claim 6, wherein said compound is non-covalently linked to the human proislet peptide.

11. A method of treating type 1 diabetes in a subject in need thereof by administering to the subject a therapeutic amount of a human proislet peptide consisting of the amino acid sequence of SEQ ID No: 7 thereby treating that pathology associated with impaired pancreatic function.

12. The method of claim 11, further comprising the step of administering one or more agents for stimulating pancreatic islet cell regeneration.

13. The method of claim 12, wherein the agents for stimulating pancreatic islet cell regeneration are selected from a member of the group consisting of one or more other human proislet peptides, amylin, SYIMLIN.TM., pramlintide, Exendin-4, Liraglutide, GLP-1 receptor agonists, GLP-1, GLP-1 analogs, hamster INGAP, and analogs thereof, GIP and Dipeptydyl peptidase-4 inhibitors.

14. The method of claim 11, further comprising the step of administering one or more agents that inhibit, block, or destroy the autoinimune cells that target pancreatic islet cells.

15. The method of claim 14, wherein the agents that inhibit, block, or destroy the autoimmune cells that target pancreatic islet cells are selected from the group consisting of anti-CD3 antibody, rapamycin, FK506, heat-shock protein 60, anti-GAD65 vaccine, mycophenolate mofetil, lysofylline, Rituximab, Campath-1H, Vitamin D, IIBC-VSO vaccine, and CD4.sup.+CD25.sup.+ antigen-specific regulatory T cells.

16. The method of claim 15, wherein the mycophenolate mofetil is coadministered with Daclizumab.

17. The method of claim 15, wherein the vitamin D is vitamin D3.

18. The method of claim 17, wherein the vitamin D3 is administered to the subject in an amount effective to maintain 25-hydroxy vitamin D above about 40 ng/mL in the subject.

19. The method of claim 11, further comprising the step of intensifying glycemic control in the subject prior to administration of the therapeutic amount of the human proislet peptide.

20. The method of claim 11, wherein the subject is being administered insulin at the time of administration of the therapeutic amount of the human proislet peptide.

21. The method of claim 20, wherein the insulin is diminished in dosage after the administration of the therapeutic amount of the human proislet peptide.

22. The method of claim 21, wherein the insulin dosage is diminished one or more times after the administration of the therapeutic amount of the human proislet peptide.

23. The method of claim 21, wherein the insulin dosage is diminished to zero.

24. A kit for treating a patient having type 1 diabetes, in a subject in need thereof comprising a therapeutically effective dose of a human proislet peptide consisting of the amino acid sequence of SEQ ID No: 7; at least one agent for stimulating pancreatic islet cell regeneration and instructions for its use.

Details for Patent 7,714,103

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2025-05-25
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 02/19/2002 ⤷  Try a Trial 2025-05-25
Hoffmann-la Roche Inc. ZENAPAX daclizumab Injection 103749 12/10/1997 ⤷  Try a Trial 2025-05-25
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 05/07/2001 ⤷  Try a Trial 2025-05-25
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.